Current Landscape of COVID-19 Therapeutics and Treatment Trials
To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.
Current Landscape of COVID-19 Therapeutics and Treatment Trials
Presenter: Tejal N. Gandhi, MD
This lecture was originally presented during Hospital Medicine Conference (2020) held on 05/13/2020.There are no relevant financial relationships to disclose for this activity.
This activity is appropriate for:
Physicians and Physicians Assistants
In the fields of:
Internal Medicine
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Original Release Date: May 2020
Termination Date: December 2020
- Sanders JM, Monogue ML, Jodlowski TZ et al. Pharmacologic Treatment of Coronavirus Disease 2019 (COVID-19) A Review. JAMA 2020;323(18): 1824-1836.
- Wang T, Zhang D, Du G et al. Remdesivir in Adults with Severe COVID-19: a Randomized, Double-blind Placebo-controlled, Multicentre Trial. Lancet 2020;Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- Geleris, J, Sun Y, Platt J et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; DOI: 10.1056/NEJMoa2012410.
- Bhimraj A, Morgan R, Shumaker AH et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2020;
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
